Fifty-three patients with multiple sclerosis were assessed in a double-blind multicentre study for the effect of amantadine. The patients were observed in general practices for up to four years. Relapses occurred in 5 of the 24 patients treated with amantadine and in 14 of the 29 placebo-treated patients, Neurological deterioration was not significantly different in the two groups.
Introduction
Multiple sclerosis (MS) was first recognized as a distinct clinical entity by Charcot in 1865, although it had previously been described as a pathological rarity in the 1830s by Curveilhier in Paris and by Carswell in London I. The cause of the disease remains a mystery". Dietary deficiency':", immune disease", genetic factors 6, 7 and virus infections" - 14 have been studied. The geographical distribution is remarkable in that the disease is less commonly observed towards the equator. The highest incidence is probably in Aberdeen15.
Acheson'" has suggested that 'it is a rare sequela of a common infection in childhood with a very long latent period'. Such a hypothesis would require modification to note that the childhood infection would be in teenagers, because young migrants from areas of high incidence tend not to develop the disease ifthey move to areas oflow incidence 17. Possibly the brain during the first decade can combat the hypothetical infection, or MS may be related to an infection of the sinuses in the skull, only developing later!", MS was not seen in the Faroe Islands until after the Second World War, during which time soldiers from the mainland had been stationed on the islands!", again leading to the supposition that an infection is responsible. However, no organism has been detected unequivocally as a causative agent.
A chance finding of improvement in the symptoms of MS in patients treated with amantadine was reported in 1974 2 0 • 2 1 • This led to the present study of the drug in a double-blind trial, Other antiviral agents used in trials in MS have been found to be too toxic or otherwise unsatisfactory for extensive study22.2 3 . Studies of other potential treatments can hardly be considered double-blind: for example, hyperbaric oxygen can be distinguished from atmospheric pressure by its effect on the ears 2 4 ,25 . MS patients often respond favourably to treatment imagined by them to be effective. Both our placebo and actively treated patients seemed to improve as soon as they started the trial, Amantadine is well tolerated and has been used for long periods in the treatment of parkinsonism. It is effective in influenza A2 2 6 (caused by an RNA virus), and in herpes zoster (related to the DNA varicella zoster virus) it was found to reduce the incidence of post-herpetic neuralgia27.
Method
In an open pilot study, amantadine 100mg either twice or three times a day in patients with MS was found to be acceptable.
The Ethical Committee of the South West London Hospital Group approved the study and the Committee on Safety of Medicines also gave a Clinical Trial Certificate.
The patients were recruited by general practitioners. At the first visit the history was noted and a full examination carried out. Patients with a hospital consultant's diagnosis ofMS were included, provided the patient agreed and was not likely to be affected by known adverse effects of amantadine. The neurological condition and the disability state were recorded according to the Kurtzke scales-", Other treatments, whether dietary, by drugs or mechanical aids, were recorded and continued or changed throughout the study as considered advisable in the patient's interest. Each patient was supplied with capsules of either amantadine (100mg twice a day) or placebo.
Patients were reassessed after one month when the dose could be increased to three capsules a day. Further increases were not allowed. Thereafter visits were at three-monthly intervals, or more frequently if needed. Whenever a relapse occurred the full details were recorded.
The study was initially intended to last for two years, but was extended to three years or longer. Patients unable to continue in the study were withdrawn and the reasons noted. They were not followed up,
Results
Of 53 patients who entered the study, 34 successfully completed at least two years ofthe trial. The remaining 19 were withdrawn for various reasons, detailed in Table 1 . The two treatment groups were similar in composition, as shown in Table 2 , although there was a majority offemales in the placebo group.
Statistical analysis of the three-monthly assessments of the placebo and amantadine group was carried out for all recorded findings, including muscle power, reflexes, coordination, sensory functions, gait, cranial nerves and bladder functions, but no significant differences were found between the two treatments. The patients' disability status was assessed regularly according to the Kurtzke scales, and at entry it varied from 'minimal signs with no disability' to 'restricted to bed, but not totally helpless'. Again no statistically significant differences 0141-0768/87/ 020091-03/$0200/0 Cl1987 The Royal Society of Medicine (Table 3) .This difference is statistically significant at the p=O.038 level. The time to first relapse during the study was longer in the amantadine-treated patients than in those on placebo (Table 4) , as was expected in view of the reduced attack rate. The difference is significant at the P=O.047 level. Eleven patients on placebo, but only 4 on amantadine, had a relapse in the first year.
Discussion
Although the deterioration in the neurological state of MS patients does not appear to be affected by amantadine, the relapse rate is reduced, and possible reasons for this include: (1) A postulated virus ofMS may be relatively resistant to attack while the disease is quiescent or slowly progressive, but a relapse may be associated with a viraemia or local spread of the virus which can then be destroyed by the antiviral drug. Amantadine affects the pH of vacuoles in leukocytes, and possibly a phagocytic mechanism'" in the brain is relevant to MS. The recently described 1 s association of MS with sinusitis could conceivably be related to leukocytes and phagocytosis.
(2) Another mechanism of action could be the mildly stimulant effect of amantadine. A mild relapse might go unnoticed by an elated patient. The need for hypnotics, antidepressants or sedatives in the two trial groups was therefore compared and it was found that in the amantadine group 5 patients needed such medication throughout the trial, compared with 7 in the placebo group. Also there were 5 patients who needed additional psychotropic medication, 3 in the amantadine and 2 in the placebo group. Psychotropic drugs were reduced for 4 patients during this time, 3 on amantadine and one on placebo. The numbers are small, but do not suggest that amantadine significantly alters the mood of patients.
(3) Relapses in MS are sometimes thought to be precipitated by events such as trauma or influenza and other virus infections'". Over the period of the study 3 patients in the amantadine group and none in the placebo group were reported to have suffered from influenza (presumably the attack was not influenza A2 which is suppressed by amantadine). No viral studies were undertaken during this trial.
Of the 53 patients, 24 had one or more infectious diseases during the study, such as bronchitis, cystitis or upper respiratory tract infections (13 on amantadine and 11 on placebo); about one-third also suffered a relapse, there being little difference between the treatment groups. This does not suggest that amantadine acts by suppressing infection.
The study of MS is difficult because the disease is variable and deterioration is slow. Placebo responses are common.". Only a large series observed carefully over at least two or three years can be expected to lead to valid observations.
This study suggests that amantadine has a beneficial effect in MS. More work needs to be done to confirm the observations, and to study the mode ofaction or physiological effect of amantadine.
Note on patient compliance
The medication was supplied in containers of 100 capsules so that this treatment could be assessed. Compliance was acceptable except for 3 patients who were withdrawn from the study because they had not taken their trial capsules. One was in the amantadine group and 2 were in the placebo group.
We are fortunate in having a group of committed general practitioners who were prepared to spend many hours regularly examining patients for this study. Apart from the findings on the relapses, much was learnt about the attitudes of patients and their relatives to MS. We certainly consider that patients should be told they have MS as soon as this diagnosis can be made with reasonable confidence'". Such knowledge is essential if patients are to enter a drug trial. We are not in favour ofthe spouse being told the truth while the patient's enquiries are circumlocuted: such an approach can lead to the patient's fears being undisclosed and create marital disharmony. It is sometimes considered that disclosure of the name of an incurable disease may cause the patient to commit suicide. Such unfortunate occurrences are very rare, though not of course unknown. Sympathetic discussion with patients is essential, and it must be explained that although the cause of MS is unknown and its treatment still problematic, much can be done to help with symptomatic treatment, mechanical aids, occasional operations'" and the support of nurses, social workers and doctors.
Our patients were pleased to help in a study to attempt to find a cure for MS and enjoyed the regular prolonged visits from their general practitioners.
Further details and statistical analysis are available from the author.
